2020 Vision For Biopharma

Welcome To The New Roaring Twenties

Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.

Sphere — Peering Into The Crystal Ball As A New Decade Approaches • Source: Shutterstock

Looking back a century, in 1920, French researchers perfected a tuberculosis vaccine for use in children from infected households. And the first tetanus anatoxin was produced. In the same year, Frederick Banting of the University of Toronto began a development journey that would eventually lead to the successful use of purified insulin in diabetics. Banting, along with John Macleod, was in 1923 awarded the Nobel Prize in Medicine for the discovery of insulin.

One hundred years later, it is a very different world for medicine discovery and development, and for patients in the...